Study populations
| Characteristic . | All patients N (%) . | Adults n (%) . | Children n (%) . |
|---|---|---|---|
| Total | 3066 (100) | 2564 (84) | 502 (16) |
| Sex, female | 1294 (42) | 1080 (42) | 214 (43) |
| Donor recipient: female/male∗ | 749 (26) | 629 (26) | 120 (25) |
| Race/ethnicity | |||
| American Indian or Alaska native | 54 (2) | 35 (1) | 19 (4) |
| Asian | 217 (7) | 161 (6) | 56 (11) |
| Black or African American | 76 (2) | 51 (2) | 25 (5) |
| Native Hawaiian/other Pacific Islander | 44 (1) | 34 (1) | 10 (2) |
| White (non-Hispanic) | 2382 (78) | 2106 (82) | 276 (55) |
| White (Hispanic) | 178 (6) | 103 (4) | 75 (15) |
| White (unknown) | 5 (<1) | 5 (<1) | 0 |
| Multiple/unknown | 110 (4) | 69 (3) | 41 (8) |
| Median age (range), y | 49.0 (0.1-78.9) | 52.8 (18.1-78.9) | 8.2 (0.1-17.9) |
| Malignant diseases | 2761 (90) | 2476 (97) | 285 (57) |
| Acute myeloid leukemia/MDS | 1355 (44) | 1256 (49) | 99 (20) |
| Myeloproliferative diseases | 213 (7) | 205 (8) | 8 (2) |
| Acute lymphoblastic leukemia | 476 (16) | 330 (13) | 146 (29) |
| Chronic leukemia (CML/CLL) | 231 (8) | 222 (9) | 9 (2) |
| Lymphoma | 308 (10) | 290 (11) | 18 (4) |
| Plasma cell disorders | 144 (5) | 144 (6) | 0 (0) |
| Biphenotypic leukemias | 30 (1) | 25 (1) | 5 (1) |
| Other | 4 (<1) | 4 (<1) | 0 (0) |
| NMD | 305 (10) | 88 (3) | 217 (43) |
| Aplastic anemia | 115 (4) | 55 (2) | 60 (12) |
| Inherited BM failure syndrome | 41 (1) | 8 (<1) | 33 (7) |
| Primary immunodeficiency disease | 80 (3) | 11 (<1) | 69 (14) |
| Primary immunodysregulatory disease | 26 (<1) | 3 (<1) | 23 (5) |
| Hemoglobinopathy (thalassemia, SCD) | 26 (<1) | 6 (<1) | 20 (4) |
| Other | 17 (<1) | 5 (<1) | 12 (2) |
| Conditioning intensity† | |||
| MA-TBI | 680 (22) | 462 (18) | 218 (43) |
| NMA | 1101 (36) | 1018 (40) | 83 (17) |
| RIC | 1285 (42) | 1084 (42) | 201 (40) |
| Donor type/graft source | |||
| HLA-identical sibling, BM | 167 (5) | 45 (2) | 122 (24) |
| HLA-identical sibling, PBSC | 731 (24) | 719 (28) | 12 (2) |
| Mismatched related | 30 (1) | 26 (1) | 4 (1) |
| Unrelated BM | 298 (10) | 158 (6) | 140 (28) |
| 10/10 HLA-matched | 243 (8) | 123 (5) | 120 (24) |
| ≤9/10 HLA-matched | 55 (2) | 35 (1) | 20 (4) |
| Unrelated PBSC | 1350 (44) | 1273 (50) | 77 (15) |
| 10/10 HLA-matched | 1102 (36) | 1041 (41) | 61 (12) |
| ≤9/10 HLA-matched | 248 (8) | 232 (9) | 16 (3) |
| Haploidentical, BM | 83 (3) | 62 (2) | 21 (4) |
| Haploidentical, PBSC | 60 (2) | 52 (2) | 8 (2) |
| Cord blood | 347 (11) | 229 (9) | 118 (24) |
| GVHD prophylaxis approaches | |||
| T-cell depletion | 134 (4) | 100 (4) | 34 (7) |
| ATG or alemtuzumab | 252 (8) | 90 (4) | 162 (32) |
| PTCY-based | 246 (8) | 219 (9) | 27 (5) |
| Methotrexate-based | 1072 (35) | 927 (36) | 145 (29) |
| MMF or sirolimus-based | 1338 (44) | 1215 (47) | 123 (25) |
| CNI only | 15 (<1) | 11 (<1) | 4 (1) |
| Other | 9 (<1) | 2 (<1) | 7 (1) |
| Characteristic . | All patients N (%) . | Adults n (%) . | Children n (%) . |
|---|---|---|---|
| Total | 3066 (100) | 2564 (84) | 502 (16) |
| Sex, female | 1294 (42) | 1080 (42) | 214 (43) |
| Donor recipient: female/male∗ | 749 (26) | 629 (26) | 120 (25) |
| Race/ethnicity | |||
| American Indian or Alaska native | 54 (2) | 35 (1) | 19 (4) |
| Asian | 217 (7) | 161 (6) | 56 (11) |
| Black or African American | 76 (2) | 51 (2) | 25 (5) |
| Native Hawaiian/other Pacific Islander | 44 (1) | 34 (1) | 10 (2) |
| White (non-Hispanic) | 2382 (78) | 2106 (82) | 276 (55) |
| White (Hispanic) | 178 (6) | 103 (4) | 75 (15) |
| White (unknown) | 5 (<1) | 5 (<1) | 0 |
| Multiple/unknown | 110 (4) | 69 (3) | 41 (8) |
| Median age (range), y | 49.0 (0.1-78.9) | 52.8 (18.1-78.9) | 8.2 (0.1-17.9) |
| Malignant diseases | 2761 (90) | 2476 (97) | 285 (57) |
| Acute myeloid leukemia/MDS | 1355 (44) | 1256 (49) | 99 (20) |
| Myeloproliferative diseases | 213 (7) | 205 (8) | 8 (2) |
| Acute lymphoblastic leukemia | 476 (16) | 330 (13) | 146 (29) |
| Chronic leukemia (CML/CLL) | 231 (8) | 222 (9) | 9 (2) |
| Lymphoma | 308 (10) | 290 (11) | 18 (4) |
| Plasma cell disorders | 144 (5) | 144 (6) | 0 (0) |
| Biphenotypic leukemias | 30 (1) | 25 (1) | 5 (1) |
| Other | 4 (<1) | 4 (<1) | 0 (0) |
| NMD | 305 (10) | 88 (3) | 217 (43) |
| Aplastic anemia | 115 (4) | 55 (2) | 60 (12) |
| Inherited BM failure syndrome | 41 (1) | 8 (<1) | 33 (7) |
| Primary immunodeficiency disease | 80 (3) | 11 (<1) | 69 (14) |
| Primary immunodysregulatory disease | 26 (<1) | 3 (<1) | 23 (5) |
| Hemoglobinopathy (thalassemia, SCD) | 26 (<1) | 6 (<1) | 20 (4) |
| Other | 17 (<1) | 5 (<1) | 12 (2) |
| Conditioning intensity† | |||
| MA-TBI | 680 (22) | 462 (18) | 218 (43) |
| NMA | 1101 (36) | 1018 (40) | 83 (17) |
| RIC | 1285 (42) | 1084 (42) | 201 (40) |
| Donor type/graft source | |||
| HLA-identical sibling, BM | 167 (5) | 45 (2) | 122 (24) |
| HLA-identical sibling, PBSC | 731 (24) | 719 (28) | 12 (2) |
| Mismatched related | 30 (1) | 26 (1) | 4 (1) |
| Unrelated BM | 298 (10) | 158 (6) | 140 (28) |
| 10/10 HLA-matched | 243 (8) | 123 (5) | 120 (24) |
| ≤9/10 HLA-matched | 55 (2) | 35 (1) | 20 (4) |
| Unrelated PBSC | 1350 (44) | 1273 (50) | 77 (15) |
| 10/10 HLA-matched | 1102 (36) | 1041 (41) | 61 (12) |
| ≤9/10 HLA-matched | 248 (8) | 232 (9) | 16 (3) |
| Haploidentical, BM | 83 (3) | 62 (2) | 21 (4) |
| Haploidentical, PBSC | 60 (2) | 52 (2) | 8 (2) |
| Cord blood | 347 (11) | 229 (9) | 118 (24) |
| GVHD prophylaxis approaches | |||
| T-cell depletion | 134 (4) | 100 (4) | 34 (7) |
| ATG or alemtuzumab | 252 (8) | 90 (4) | 162 (32) |
| PTCY-based | 246 (8) | 219 (9) | 27 (5) |
| Methotrexate-based | 1072 (35) | 927 (36) | 145 (29) |
| MMF or sirolimus-based | 1338 (44) | 1215 (47) | 123 (25) |
| CNI only | 15 (<1) | 11 (<1) | 4 (1) |
| Other | 9 (<1) | 2 (<1) | 7 (1) |
ATG, antithymocyte globulin; BM, bone marrow; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; CNI, calcineurin inhibitor; MA-TBI, myeloablative Total body irradiation; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; NMA, nonmyeloablative; PBSC, peripheral blood stem cells; PTCY, posttransplant cyclophosphamide; RIC, reduced-intensity conditioning; SCD, sickle cell disease.
Missing donor sex information for 129 of 3066 patients (106 adults and 23 children).
MA-TBI (TBI ≥12 Gy–containing regimens); NMA (fludarabine 90 mg/m2 and 2-3 Gy TBI or fludarabine ≤150 mg/m2; cyclophosphamide 29 mg/kg and 2-3 Gy TBI); and RIC (all other conditioning regimens including 4 Gy TBI–containing regimens).